The results of the study could have implications for liquid biopsy developers that aim to pick out patients more likely to respond to immunotherapies.
Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.
Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.
Guardant is alleging that Foundation's advertising of its own products has harmed both Guardant and cancer patients.
The registry collects data on cancer genetics and aims to provide patients with access to quality NGS testing, among other things.
Guardant will provide its Guardant360 liquid biopsy cancer assay to Pfizer's oncology business unit for use in clinical trials.
The belief among genomics experts that one day drugs would be given based on genomic abnormalities that cut across tumor types became reality this week.
Guardant said Guardant360 is the first liquid biopsy permitted by New York's CLEP, and the approval means the test can be ordered in all 50 states.
The coverage decision limits the test to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue-based testing.
The money will fund a new plan to sequence tumor DNA from more than 1 million cancer patients. The firm also announced a new JV in Asia, the Middle East, and Africa.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.